AR076640A1 - Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura - Google Patents
Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufacturaInfo
- Publication number
- AR076640A1 AR076640A1 ARP100100676A ARP100100676A AR076640A1 AR 076640 A1 AR076640 A1 AR 076640A1 AR P100100676 A ARP100100676 A AR P100100676A AR P100100676 A ARP100100676 A AR P100100676A AR 076640 A1 AR076640 A1 AR 076640A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- formulation
- article
- manufacture
- stabilizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicacion 1: Una formulacion que comprende una cantidad terapéuticamente eficaz de un anticuerpo en un tampon de histidina-arginina, pH 4,5 a 6,5. Reivindicacion 7: La formulacion de acuerdo con la reivindicacion 1, que además comprende un surfactante. Reivindicacion 8: La formulacion de acuerdo con la reivindicacion 7, en donde el surfactante es polisorbato. Reivindicacion 18: La formulacion de acuerdo con la reivindicacion 1, que además comprende metionina. Reivindicacion 20: La formulacion de acuerdo con la reivindicacion 1, que además comprende EDTA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15833109P | 2009-03-06 | 2009-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076640A1 true AR076640A1 (es) | 2011-06-29 |
Family
ID=42154725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100100676A AR076640A1 (es) | 2009-03-06 | 2010-03-05 | Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura |
Country Status (18)
Country | Link |
---|---|
US (1) | US8318161B2 (es) |
EP (1) | EP2403874A1 (es) |
JP (1) | JP2012519706A (es) |
KR (1) | KR20110128333A (es) |
CN (1) | CN102414221A (es) |
AR (1) | AR076640A1 (es) |
AU (1) | AU2010221156A1 (es) |
BR (1) | BRPI1006519A2 (es) |
CA (1) | CA2754528A1 (es) |
CL (1) | CL2011002194A1 (es) |
IL (1) | IL214956A0 (es) |
MX (1) | MX2011009306A (es) |
PE (1) | PE20120359A1 (es) |
RU (1) | RU2011140498A (es) |
SG (1) | SG174258A1 (es) |
TW (1) | TW201039854A (es) |
WO (1) | WO2010102241A1 (es) |
ZA (1) | ZA201106503B (es) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2314315T3 (en) | 1999-06-01 | 2015-02-02 | Biogen Idec Inc | Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
PL367324A1 (en) | 2001-04-13 | 2005-02-21 | Biogen, Inc. | Antibodies to vla-1 |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
EA012801B1 (ru) | 2005-06-14 | 2009-12-30 | Эмджен Инк. | Самобуферирующиеся композиции белков |
EP2839843B1 (en) | 2006-05-25 | 2018-06-20 | Biogen MA Inc. | VLA-1 antagonist for use in treating stroke |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
CA2744670C (en) * | 2009-01-06 | 2018-05-15 | Ziad Mallat | A b cell depleting agent for the treatment of atherosclerosis |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
MY159156A (en) | 2009-12-21 | 2016-12-15 | Genentech Inc | Antibody formulation |
AU2013202276B2 (en) * | 2009-12-21 | 2016-03-24 | Genentech, Inc. | Antibody formulation |
EP3345615B1 (en) | 2010-03-01 | 2019-10-16 | Bayer Healthcare LLC | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
KR101878369B1 (ko) | 2010-03-22 | 2018-07-16 | 제넨테크, 인크. | 단백질-함유 제제의 안정화에 유용한 조성물 및 방법 |
WO2012016227A2 (en) | 2010-07-29 | 2012-02-02 | Xencor, Inc. | Antibodies with modified isoelectric points |
TW201213342A (en) | 2010-09-17 | 2012-04-01 | Baxter Int | Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral pH |
US8945559B2 (en) * | 2010-10-06 | 2015-02-03 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies |
UA111731C2 (uk) * | 2010-10-06 | 2016-06-10 | Рідженерон Фармасьютікалз, Інк. | Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти |
KR20200133826A (ko) | 2011-01-28 | 2020-11-30 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 특정 대상자 그룹의 치료 방법에 이용하기 위한 pcsk9에 대한 인간 항체 |
AR086074A1 (es) * | 2011-04-26 | 2013-11-13 | Genentech Inc | Composiciones y metodo para tratar enfermedades autoinmunes |
AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
EA028278B1 (ru) | 2011-09-16 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9) |
CN104039826A (zh) | 2011-10-31 | 2014-09-10 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
CN104169299B (zh) | 2012-01-23 | 2018-06-05 | 瑞泽恩制药公司 | 含抗Ang-2 抗体的稳定化制剂 |
US10316095B2 (en) * | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
WO2014084508A1 (ko) | 2012-11-27 | 2014-06-05 | (주)알테오젠 | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
WO2014113510A1 (en) * | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
WO2014145907A1 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Targeting t cells with heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
KR102251127B1 (ko) | 2013-07-12 | 2021-05-11 | 제넨테크, 인크. | 이온 교환 크로마토그래피 입력 최적화의 설명 |
CN110559435B (zh) | 2013-09-11 | 2023-10-20 | 伊戈尔生物药品股份有限公司 | 包含离子性液体的液体蛋白质制剂 |
KR20210041101A (ko) * | 2013-10-24 | 2021-04-14 | 아스트라제네카 아베 | 안정한 수성 항체 제제 |
CN118105481A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
CN106211773B (zh) | 2014-02-11 | 2021-09-03 | 威特拉公司 | 用于登革病毒的抗体分子及其应用 |
JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd38及びcd3に結合する二重特異性抗体 |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
CN107206068A (zh) | 2014-07-16 | 2017-09-26 | 赛诺菲生物技术公司 | 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法 |
AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
JP2017537084A (ja) | 2014-11-12 | 2017-12-14 | トラコン ファーマシューティカルズ、インコーポレイテッド | 抗エンドグリン抗体及びその用途 |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
MA41019A (fr) | 2014-11-26 | 2021-05-05 | Xencor Inc | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
WO2017031151A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
CA3018216A1 (en) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulations of antibody molecules to dengue virus |
EP3463416A1 (en) | 2016-05-31 | 2019-04-10 | CardioVax, LLC | Methods for diagnosing and treating systemic lupus erythematosus |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
RU2022104399A (ru) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR102649972B1 (ko) | 2016-10-14 | 2024-03-22 | 젠코어 인코포레이티드 | IL15/IL15Rα 이종이량체 Fc-융합 단백질 |
EP3528787A4 (en) | 2016-10-21 | 2020-05-06 | Amgen Inc. | PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
CA3067603A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
CA3086199A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
CN111954678A (zh) * | 2018-04-02 | 2020-11-17 | 美国安进公司 | 厄瑞努单抗组合物及其用途 |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
EP3773695A4 (en) * | 2018-04-10 | 2021-12-22 | Dr. Reddy's Laboratories Ltd. | STABLE ANTIBODY FORMULATION |
EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
WO2019232081A1 (en) * | 2018-05-29 | 2019-12-05 | Abcentra, Llc | Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis |
US20210155682A1 (en) * | 2018-07-02 | 2021-05-27 | Abcentra, Llc | Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
MX2021010390A (es) | 2019-03-01 | 2021-11-17 | Xencor Inc | Anticuerpos heterodimericos que se unen a enpp3 y cd3. |
US20220403013A1 (en) * | 2019-11-12 | 2022-12-22 | Abcentra, Llc | Methods and compositions for treating cancer |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
WO2021240458A2 (en) * | 2020-05-28 | 2021-12-02 | Kashiv Biosciences, Llc | An improved process of storing and preparing the protein |
AU2021316017A1 (en) | 2020-07-31 | 2023-02-16 | F. Hoffmann-La Roche Ag | Anti-integrin beta7 antibody formulations and devices |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
WO2024090488A1 (ja) * | 2022-10-26 | 2024-05-02 | 日本メジフィジックス株式会社 | 放射性医薬組成物 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1064396A (en) * | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
US4075193A (en) * | 1976-11-26 | 1978-02-21 | Parke, Davis & Company | Process for producing intravenous immune globulin |
AT359641B (de) | 1978-09-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates |
US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
US4499073A (en) * | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US4940782A (en) * | 1987-06-08 | 1990-07-10 | G. D. Searle & Co. | Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore |
ES2044941T5 (es) | 1987-08-21 | 1999-02-16 | Mallinckrodt Group Inc | Estabilizador de hormonas promotoras del crecimiento. |
US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
CA1331133C (en) * | 1988-03-01 | 1994-08-02 | Michael Jon Pikal | Pharmaceutical growth hormone formulations |
EP0365685B1 (en) * | 1988-03-30 | 1995-01-18 | Toray Industries, Inc. | Freeze-dried composition comprising a horseradish peroxidase-labelled Fab' fragment of an anti-human interferon-beta monclonal antibody and trehalose; EIA kit containing the composition |
US5215743A (en) * | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
GB2218703B (en) * | 1988-05-10 | 1992-10-28 | Sumitomo Chemical Co | Human monoclonal antibody to p.aeruginosa: its production and use |
JPH03504605A (ja) | 1988-05-27 | 1991-10-09 | セントカー・インコーポレーテツド | 抗体産生物の凍結乾燥した配合物 |
JPH04504253A (ja) | 1989-03-27 | 1992-07-30 | セントカー・インコーポレーテツド | IgM抗体の安定化のための配合物 |
ZA902663B (en) | 1989-04-07 | 1991-12-24 | Syntex Inc | Interleukin-1 formulation |
DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
WO1992017207A1 (en) | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
JP2966592B2 (ja) | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
ATE233813T1 (de) | 1991-08-14 | 2003-03-15 | Genentech Inc | Veränderte immunglobuline für spezifische fc- epsilon rezeptoren |
US6685939B2 (en) * | 1991-08-14 | 2004-02-03 | Genentech, Inc. | Method of preventing the onset of allergic disorders |
GB9120304D0 (en) | 1991-09-24 | 1991-11-06 | Erba Carlo Spa | Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor |
US5849700A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
CH684164A5 (de) | 1992-01-10 | 1994-07-29 | Rotkreuzstiftung Zentrallab | Intravenös anwendbare Immunglobulinlösung. |
AU670793B2 (en) * | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
EP0748377B1 (en) | 1994-03-04 | 2008-07-16 | Genentech, Inc. | IMPROVED DNase LIQUID SOLUTIONS |
US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
GB9418092D0 (en) * | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
ATE202783T1 (de) | 1994-12-28 | 2001-07-15 | Rhodia Chimie Sa | Optisch aktive diphosphine und herstellungsverfahren durch auftrennung der racematmischung |
US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP1516628B1 (en) | 1995-07-27 | 2013-08-21 | Genentech, Inc. | Stable isotonic lyophilized protein formulation |
US6686191B1 (en) | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
DE59710863D1 (de) | 1996-01-25 | 2003-11-20 | Schering Ag | Verbesserte kontrastmittenlösungen für die intravasale anwendung |
KR100236393B1 (ko) | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
JP4344404B2 (ja) | 1996-02-09 | 2009-10-14 | アムジェン インコーポレイテッド | インターロイキン―1インヒビターおよび制御放出ポリマーを含む組成物 |
TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US6096872A (en) * | 1997-10-14 | 2000-08-01 | Ortho Diagnostic Systems, Inc. | Viral clearance process |
US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
WO2000015260A1 (en) | 1998-09-16 | 2000-03-23 | Tanox, Inc. | Anti-ige gene therapy |
GB9820525D0 (en) * | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
EP1220682B1 (en) * | 1999-10-04 | 2006-11-22 | Novartis Vaccines and Diagnostics, Inc. | Stabilized liquid polypeptide-containing pharmaceutical compositions |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
GB0023383D0 (en) * | 2000-09-23 | 2000-11-08 | Synprotec Ltd | 3,5-Bis (Trifluormethyl)Benzene derivatives |
CA2425765A1 (en) | 2000-10-11 | 2003-04-11 | Daiichi Pharmaceutical Co., Ltd. | Novel drugs for liver diseases |
AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
KR20100031769A (ko) | 2000-12-28 | 2010-03-24 | 알투스 파마슈티컬스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
DE60235013D1 (de) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
US8372798B2 (en) * | 2001-10-16 | 2013-02-12 | Endo Pharmaceuticals Colorado, Inc. | High-concentration protein formulations and method of manufacture |
EP1441589B1 (en) * | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
WO2004030607A2 (en) * | 2002-10-04 | 2004-04-15 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2007092772A2 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
EP2114451A2 (en) * | 2007-01-09 | 2009-11-11 | Wyeth a Corporation of the State of Delaware | Anti-il-13 antibody formulations and uses thereof |
US20110014203A1 (en) * | 2007-12-28 | 2011-01-20 | Fredrik Nilsson | Formulation |
AU2010286532A1 (en) * | 2009-08-28 | 2012-04-12 | Bioinvent International | Methods of treatment using anti-oxidized LDL antibodies |
-
2010
- 2010-03-05 RU RU2011140498/10A patent/RU2011140498A/ru not_active Application Discontinuation
- 2010-03-05 PE PE2011001591A patent/PE20120359A1/es not_active Application Discontinuation
- 2010-03-05 JP JP2011553145A patent/JP2012519706A/ja not_active Withdrawn
- 2010-03-05 TW TW099106511A patent/TW201039854A/zh unknown
- 2010-03-05 BR BRPI1006519A patent/BRPI1006519A2/pt not_active IP Right Cessation
- 2010-03-05 US US12/718,783 patent/US8318161B2/en not_active Expired - Fee Related
- 2010-03-05 MX MX2011009306A patent/MX2011009306A/es not_active Application Discontinuation
- 2010-03-05 CN CN2010800194416A patent/CN102414221A/zh active Pending
- 2010-03-05 CA CA2754528A patent/CA2754528A1/en not_active Abandoned
- 2010-03-05 SG SG2011063922A patent/SG174258A1/en unknown
- 2010-03-05 EP EP10707789A patent/EP2403874A1/en not_active Withdrawn
- 2010-03-05 AR ARP100100676A patent/AR076640A1/es unknown
- 2010-03-05 WO PCT/US2010/026410 patent/WO2010102241A1/en active Application Filing
- 2010-03-05 AU AU2010221156A patent/AU2010221156A1/en not_active Abandoned
- 2010-03-05 KR KR1020117023363A patent/KR20110128333A/ko not_active Application Discontinuation
-
2011
- 2011-09-04 IL IL214956A patent/IL214956A0/en unknown
- 2011-09-06 ZA ZA2011/06503A patent/ZA201106503B/en unknown
- 2011-09-06 CL CL2011002194A patent/CL2011002194A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG174258A1 (en) | 2011-10-28 |
BRPI1006519A2 (pt) | 2016-08-09 |
US8318161B2 (en) | 2012-11-27 |
IL214956A0 (en) | 2011-11-30 |
AU2010221156A1 (en) | 2011-09-22 |
EP2403874A1 (en) | 2012-01-11 |
JP2012519706A (ja) | 2012-08-30 |
CN102414221A (zh) | 2012-04-11 |
US20100239567A1 (en) | 2010-09-23 |
RU2011140498A (ru) | 2013-04-20 |
KR20110128333A (ko) | 2011-11-29 |
PE20120359A1 (es) | 2012-04-13 |
TW201039854A (en) | 2010-11-16 |
CL2011002194A1 (es) | 2012-07-20 |
WO2010102241A1 (en) | 2010-09-10 |
MX2011009306A (es) | 2011-10-13 |
CA2754528A1 (en) | 2010-09-10 |
ZA201106503B (en) | 2012-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076640A1 (es) | Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura | |
AR079556A1 (es) | Formacion de anticuerpos | |
AR086237A1 (es) | FORMULACION PARA ANTICUERPO ANTI-a4b7 | |
AR086823A1 (es) | Formulaciones de anticuerpo anti-c-met, metodos | |
BR112017027813A2 (pt) | conjugados de agente de ligação-droga (adcs) e conjugados de agente de ligação-pró-droga (apdcs) tendo grupos enzimaticamente cliváveis | |
AR079821A1 (es) | Cepas y metodo para la produccion de metionina | |
CL2013003214A1 (es) | Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol. | |
AR086074A1 (es) | Composiciones y metodo para tratar enfermedades autoinmunes | |
AR076440A1 (es) | Articulo para fumar. | |
BR112012028292A2 (pt) | artigo, método de dopagem de grafeno, fotodetector e dispositivo | |
AR075220A1 (es) | Composicion detergente liquida para el lavado manual de vajilla | |
CO6351724A2 (es) | Inhibidores de cmet | |
CO6410285A2 (es) | Métodos para reducir la proliferación y viabilidad de los agentes microbianos | |
CR20120387A (es) | Composiciones minerales queladas orgánicamente y métodos de ellas | |
CL2012002946A1 (es) | Metodo para fabricar un artículo para fumar que comprende aplicar uno o más parches de material a la superficie exterior del envoltorio; y artículo para fumar. | |
CL2011002669A1 (es) | Tabaco tratado para un articulo para fumar en que el tabaco porta diluyente y material de barrera en donde el diluyente se aplica al tabaco antes que o simultaneamente con el material de barrera, articulo para fumar; y metodo para producir el tabaco tratado. | |
GT201200293A (es) | Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs) | |
BRPI0710405B8 (pt) | comprimido de racecadotril, processo de preparação de um comprimido de racecadotril e uso de racecadotril | |
CU23795A3 (es) | Formulaciones líquidas de anticuerpo antirrábico | |
AR114921A2 (es) | Método para preparar 2-amino-n-(2,2,2-trifluoroetil)acetamida | |
AR082422A1 (es) | Composicion detergente liquida | |
CL2013001640A1 (es) | Composicion cementicia que comprende un acelerante, una fuente de sulfato de calcio y un cemento formador de etringita; metodo de aplicacion de dicha composicion a una superficie; metodo para formar un miembro de concreto; y concreto que comprende a dicha composicion. | |
AR060482A1 (es) | Composicion para el tratamiento de telas disenada para ser agregada en el enjuage | |
BR112015023531A2 (pt) | métodos para formação de artigos absorventes com substratos não tecidos | |
EA201101443A1 (ru) | Устройство и способ изготовления абсорбирующего изделия |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |